Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77257.870.0224%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

OnKure Therapeutics Inc

OKURNASDAQ
Trade with Public
Trade with Public
$3.10
-0.17-5.2%
At close: Sep 11, 5:00 PM EST
$3.10
N/A
After Hours: Sep 11, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

OnKure Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for OnKure Therapeutics (OKUR).

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingOutperform# Analysts4Avg. Consensus PT$26Upside to Avg. PT+738.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026OppenheimerLeland GershellPT CutOutperform$30→$14
Jul 20, 2026HC Wainwright & Co.Robert BurnsPT CutBuy$27→$21
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14

Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21

HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.
Benzinga Newsdesk

PRO
'[HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $27

HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $34 to $27.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $34 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Buy and maintains $34 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $34

HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $40 to $34.
Benzinga Newsdesk

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved